Filtered By:
Therapy: Immunotherapy
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 2373 results found since Jan 2013.
Oncology News Quiz 2015: 'Unprecedented Survival' Was How Long?Oncology News Quiz 2015: 'Unprecedented Survival' Was How Long?
Immunotherapy continues to make its mark on oncology and, overall, cancer patients are living for longer. Take a look back over the biggest oncology news stories of the year, and see if you can remember the details. Medscape Medical News
Source: Medscape Medical News Headlines - December 22, 2015 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Merck Announces Initial Results for KEYTRUDA ® (pembrolizumab) with Novel Immunotherapy Combinations from Three Investigational Studies Presented at the Society for Melanoma Research International Congress
Dateline City:
KENILWORTH, N.J. In Addition, Longer Term Follow-Up Single-Agent Data for KEYTRUDA Shows Continued Superior Overall Response Rate and Progression Free Survival Compared to Ipilimumab KENILWORTH, N.J.--( BUSINESS WIRE )--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced findings from three studies investigating the use of
KEYTRUDA ® (pembrolizumab), the company ’s anti-PD-1 therapy,
in combination with three other immunotherapies – epacadostat, IMLYGIC TM
(talimogene laherparepvec), and ipilimumab – in patients with advance...
Source: Merck.com - Product News - November 21, 2015 Category: Drugs & Pharmacology Tags: Prescription Medicine News Research and Development News Corporate News Latest News #Merck #MRK $MRK cancer Keytruda MSD NYSE:MRK Source Type: news
Merck ’s KEYTRUDA® (pembrolizumab) Significantly Improves Survival Compared to Chemotherapy in Previously-Treated Patients with Non-Small Cell Lung Cancer Whose Tumors Express Any Level of PD-L1
Dateline City:
KENILWORTH, N.J. KEYNOTE-010 Published in The Lancet and to be Presented at the European Society for Medical Oncology (ESMO) Asia 2015 Congress KENILWORTH, N.J.--( BUSINESS WIRE )--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced results from the pivotal KEYNOTE-010 study, the first
study of its kind to evaluate the potential of an immunotherapy compared
to chemotherapy based on prospective measurement of PD-L1 expression in
patients with advanced non-small cell lung cancer (NSCLC). Language:
English Contact: Merc...
Source: Merck.com - Product News - December 19, 2015 Category: Drugs & Pharmacology Tags: Oncology Newsroom Prescription Medicine News Corporate News Latest News #Merck #MRK $MRK Keytruda Melanoma MSD pembrolizumab Source Type: news
Top 10 Mesothelioma and Asbestos News Stories of 2020
Growing allegations of asbestos-contaminated talc in various consumer products, coupled with historic approval of a new treatment for pleural mesothelioma, made 2020 a year filled with both anxiety and hope.
Johnson & Johnson stopped selling its iconic baby powder in May after being hit by thousands of lawsuits contending its talc-based product was causing various cancers, including ovarian cancer and malignant mesothelioma.
The U.S. Food and Drug Administration approved the immunotherapy combination of Opdivo and Yervoy in October, the first new drug regimen approved for first-line treatment of unresectable disease in...
Source: Asbestos and Mesothelioma News - December 15, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news
Top 10 Mesothelioma News Stories of 2017
Every year, mesothelioma specialists and researchers make strides to advance the standard of care, improve treatment strategies and develop new diagnostic practices.
Mesothelioma remains a rare cancer, with an estimated 3,000 people diagnosed each year in the U.S., but the fight to find a cure only grows stronger.
And while researchers are busy finding breakthroughs in care, advocates are hard at work campaigning for a ban on asbestos, the main cause of mesothelioma.
This was a memorable year on both fronts.
Immunotherapy continues to be the hot topic among emerging treatments. Drugs such as pembrolizumab (Keytruda) and ni...
Source: Asbestos and Mesothelioma News - December 22, 2017 Category: Environmental Health Authors: Daniel King Tags: canada asbestos ban Food and Drug Administration Furthering Asbestos Claims Transparency Act keytruda Medical marijuana mesothelioma mesothelioma vaccine Opdivo Scott Pruitt talcum powder lawsuit yervoy Source Type: news
Many Breast Cancer Patients Can Safely Skip Chemo, Major Study Finds
CHICAGO (CBS News/AP) — Most women with the most common form of early-stage breast cancer can safely skip chemotherapy without hurting their chances of beating the disease, doctors are reporting from a landmark study that used genetic testing to gauge each patient’s risk.
The study is the largest ever done of breast cancer treatment, and the results are expected to spare up to 70,000 patients a year in the United States and many more elsewhere the ordeal and expense of these drugs.
“The impact is tremendous,” said the study leader, Dr. Joseph Sparano of Montefiore Medical Center in New York. Most wo...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - June 4, 2018 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health News Breast Cancer Chemotherapy Source Type: news
Allergic To Dogs? It Might Only Be Males, Boston Doctor Says
By Sandee LaMotte, CNN
(CNN) — Love dogs but find yourself uncontrollably sneezing around some of them? There might be a solution that’s easier than allergy shots. Neuter your male pup or opt for a female dog.
“Up to 30% of people who are allergic to dogs are actually allergic to one specific protein that’s made in the prostate of a dog,” said Dr. Lakiea Wright, an allergist at Brigham and Women’s Hospital in Boston.
While the protein was identified years ago, reliable lab tests for the allergen that were approved by the US Food and Drug Administration were only developed in the last f...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - January 7, 2020 Category: Consumer Health News Authors: Health – CBS Boston Tags: Boston News Health Offbeat Allergies Brigham & Women's Hospital CNN Pet Allergies Source Type: news
Study: New Form Of Coronavirus Spreads Faster, But Doesn ’ t Make People Sicker
(CNN) — A global study has found strong evidence that a new form of the coronavirus has spread from Europe to the US. The new mutation makes the virus more likely to infect people but does not seem to make them any sicker than earlier variations of the virus, an international team of researchers reported Thursday.
“It is now the dominant form infecting people,” Erica Ollmann Saphire of the La Jolla Institute for Immunology and the Coronavirus Immunotherapy Consortium, who worked on the study, told CNN.
“This is now the virus.”
The study, published in the journal Cell, builds on some earlier wo...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - July 3, 2020 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health News Syndicated CBSN Boston CNN Coronavirus Source Type: news
'New Era' of Bladder Cancer Immunotherapy Under Way'New Era' of Bladder Cancer Immunotherapy Under Way
For 40 years, not much has happened in the use of immunotherapy for bladder cancer. That is about to change. Medscape Medical News
Source: Medscape Medical News Headlines - May 18, 2014 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Long-Lasting Responses With Immunotherapy in Melanoma Long-Lasting Responses With Immunotherapy in Melanoma
An update on data from early clinical trials showed that patients are surviving for years on immunotherapy with nivolumab, ipilimumab, and a combination of the two. Medscape Medical News
Source: Medscape Medical News Headlines - November 29, 2014 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Early Oral Peanut Immunotherapy Successful in PreschoolersEarly Oral Peanut Immunotherapy Successful in Preschoolers
Results from the DEVIL study show that oral immunotherapy for peanut allergy is safe and effective in preschool-aged children. Medscape Medical News
Source: Medscape Medical News Headlines - February 24, 2015 Category: Consumer Health News Tags: Allergy & Clinical Immunology News Source Type: news
Sublingual Immunotherapy Safe Alternative for Peanut AllergySublingual Immunotherapy Safe Alternative for Peanut Allergy
Long-term sublingual immunotherapy for peanut allergy can provide a lasting benefit in some children, although the effect is not as strong as with oral options. Medscape Medical News
Source: Medscape Medical News Headlines - February 25, 2015 Category: Consumer Health News Tags: Allergy & Clinical Immunology News Source Type: news
Atopy Can Predict Oral Immunotherapy Adverse Event RiskAtopy Can Predict Oral Immunotherapy Adverse Event Risk
Patients with allergic rhinitis or a large wheal on a skin-prick test are at high risk for adverse events from oral immunotherapy, and should be counseled accordingly, new research suggests. Medscape Medical News
Source: Medscape Medical News Headlines - February 27, 2015 Category: Consumer Health News Tags: Allergy & Clinical Immunology News Source Type: news
FDA Approves Nivolumab, First Immunotherapy for Lung CancerFDA Approves Nivolumab, First Immunotherapy for Lung Cancer
Approved 3 months ahead of schedule, nivolumab is the first immunotherapy to have shown a survival benefit in non-small cell lung cancer. News Alerts
Source: Medscape Medical News Headlines - March 4, 2015 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news
